

RCI MODEL RULES COMMITTEE
PETITION FOR NEW RULE OR CHANGE TO EXISTING RULE

Please submit the following information to the Chair of the Model Rules Committee at least 45 days in advance of the next scheduled committee meeting to www.rules@arci.com.

Your Contact Information:

Name:	Michael Tanner/ Michele Kopiec/ TC Lane
Organization:	USTA
Address:	
Phone(s):	
Fax #:	
E-mail Address:	Michele.kopiec@ustrotting.com

A. Brief Description of the Issue: *To establish threshold levels for multiple substances with levels that have been recommended by the HRMC.*

B. Discussion of the Issue and Problem

Provide background on the issue to build context. Address the following:

- *What specific problems or concerns are involved in this issue?* Screening limits for certain drugs, listed below, have been researched and threshold levels recommended by published papers, see below.
- *Who does the issue affect?* Standarbred Industry
- *What existing model rules relate to this issue?* Uniform Classification Guidelines
- *Provide relevant quantitative or statistical information if possible:*
 - **Benzoylecgonine (BZE) – 1 ng/ml in plasma.** Supported by a recently released paper co-authored by HRMC members Drs. Fenger, Maylin, and Tobin.
 - **Aminorex – 30ng/ml in urine.** Based upon previously published peer-reviewed studies. This recommendation solely addresses an environmental contamination threshold which could be exceeded by the administration of Levamisole.
 - **Pemoline – 2ng/ml in plasma.** Supported by a paper published in late 2024 by Drs. Fenger, Maylin, and Tobin.
 - **Methamphetamine – 1 ng/ml in plasma.** Supported by previously published (and peer-reviewed) papers.
 - **Synephrine – 50 ng/ml in urine.** Based upon previously published peer-reviewed studies.

C. Possible Solutions and Impact

Provide possible recommendations to solve the problem. Include details on each proposed solution such as

- *What solution does this proposal provide? Addresses the testing levels for multiple substances in the Standardbred industry.*
- *How will the solution fix the problem? Provides thresholds.*
- *How will the change affect any entities or stakeholders? Self-explanatory*
- *How will you or your organization be affected by the proposed change? As above*
- *What are the benefits of the proposed change? As above*
- *What are the possible drawbacks of the proposed change? None known*
- *Identify possible fiscal impact of the recommended change. None*

D. Please identify any affected stakeholder groups that expressed support or opposition.

(These stakeholders may include the racetracks, breed registries, owners, trainers, jockeys, veterinarians, or others.)

- *For those stakeholder groups that have expressed an opinion, please list the points on which they agree or disagree, and the arguments they have expressed.*
- *Are there any affected stakeholder groups that have not been consulted on this proposal?*
- *Please submit any formal letters of support or opposition by stakeholder groups. The USTA Board of Directors has declared that the Harness Racing Medication Collaborative has been established as the entity to develop thresholds and/or screening levels for medications in use in harness racing.*

E. Attach the model rule language you are proposing. Please show new language with underlined text. If you are proposing that current model rule language be eliminated, please strikeout the language to be deleted.

Benzoylcegonine (BZE) – 1 ng/ml in plasma.

Aminorex – 30ng/ml in urine

Pemoline – 2ng/ml in plasma

Methamphetamine – 1 ng/ml in plasma

Synephrine – 50 ng/ml in urine

F. Do any racing jurisdictions currently have a version of this rule in effect? If yes, please attach copies of those rules.

G. Review the RCI Model Rules and identify any other Model Rules this change would affect and submit proposed amendments to those rules to comply with changes that would be made by this proposal. *Uniform Classification Guidelines*

FILING THIS REQUEST WITH RCI DOES NOT GUARANTEE YOUR PROPOSAL WILL BE CONSIDERED BY THE MODEL RULES COMMITTEE. IF YOU HAVE OPPOSITION FROM AN INTERESTED PARTY, YOU ARE STRONGLY ENCOURAGED TO TRY TO REACH CONSENSUS PRIOR TO FILING THIS FORM.